Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Gardinier, US
Clayton F. Gardinier, Lafayette, LA US
| Patent application number | Description | Published |
|---|---|---|
| 20080215158 | Prosthetic hip joint having polycrystalline diamond articulation surfaces and at least one solid polycrystalline diamond compact - A prosthetic joint in which at least one bearing component is made from solid diamond. | 09-04-2008 |
| 20090263643 | USE OF SN AND PORE SIZE CONTROL TO IMPROVE BIOCOMPATIBILITY IN POLYCRYSTALLINE DIAMOND COMPACTS - Polycrystalline diamond compacts for use in artificial joints achieve reduced corrosion and improved biocompatibility through the use of solvent metal formulations containing tin and through the control of solvent metal pore size, particularly in inner layers of the compact. Solvent metal formulations containing tin have been discovered which provide sintering ability, part strength, and grind resistance comparable to levels achieved by using CoCrMo solvent metals. It has been discovered that limiting the solvent metal pore size in the diamond layers minimizes or eliminates the occurance of micro cracks in the solvent metal and significantly reduces the corrosion of the compact as manifested by the release of heavy metal ions from the compact. Polycrystalline diamond compacts which utilize both the solvent metal formulations containing tin and the control of pore sizes achieve significantly reduced corrosion and improved biocompatibility compared to prior art polycrystalline diamond compacts. | 10-22-2009 |
| 20100198353 | USE OF Ti and Nb CEMENTED IN TiC IN PROSTHETIC JOINTS - An improved composition of titanium sintered titanium carbide is provided. The composition provides an improved degree of strength and toughness and improved compatibility with medical imaging. The composition provides good compatibility with sintered polycrystalline diamond, achieving a good mechanical fit in terms of the combined compressibility and thermal expansion during the sintering process to minimize stress or cracking between the substrate and the diamond layer. | 08-05-2010 |
Clayton F. Gardinier, American Fork, UT US
| Patent application number | Description | Published |
|---|---|---|
| 20090046967 | BEARINGS, RACES AND COMPONENTS THEREOF HAVING DIAMOND AND OTHER SUPERHARD SURFACES - Diamond bearings and bearing components are disclosed. Some embodiments of the bearings and bearing components include polycrystalline diamond compacts sintered under high pressure and high temperature to create a diamond table chemically and mechanically bonded to a substrate, the diamond table presenting a durable and thermally stable load bearing and articulation surface. | 02-19-2009 |
| 20100025898 | USE OF Ti AND Nb CEMENTED TiC IN PROSTHETIC JOINTS - Use of Ti and Nb cemented in TiC in prosthetic joints, such as prosthetic joint components made from sintered superhard materials. | 02-04-2010 |
Kevin Matthew Gardinier, Fishers, IN US
| Patent application number | Description | Published |
|---|---|---|
| 20090093456 | NOVEL MCH RECEPTOR ANTAGONISTS - The present invention relates to a melanin concentrating hormone antagonist compound of formula (1): wherein R | 04-09-2009 |
| 20090170913 | NOVEL MCH RECEPTOR ANTAGONISTS - The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar | 07-02-2009 |
| 20100016350 | NOVEL MCH RECEPTOR ANTAGONISTS - The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R | 01-21-2010 |
| 20100069352 | 5- [4-(AZETIDIN-3-YLOXY)-PHENYL]-2-PHENYL-5H-THIAZOLO[5,4-C] PYRIDIN-4-ONE DERIVATIVES AND THEIR USE AS MCH RECEPTOR ANTAGONISTS - The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein “ - - - ” is absent or is optionally a bond; q is 1 or 2; R | 03-18-2010 |
Kevin Matthew Gardinier, Indianapolis, IN US
| Patent application number | Description | Published |
|---|---|---|
| 20080287504 | CB1 MODULATOR COMPOUNDS - Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. | 11-20-2008 |